TECNIS MULTIFOCAL FOLDABLE POSTERIOR CHAMBER INTRAOCULAR LENS (IOL)
Johnson & Johnson Surgical Vision, Inc. · Decision date Jan 16, 2009
What did the FDA approve?
The FDA database entry records an original PMA approval dated January 16, 2009, for the TECNIS Multifocal foldable posterior chamber intraocular lenses, models ZM900 and ZMA00. The applicant is Johnson & Johnson Surgical Vision, Inc., and the device is classified under product code MFK as a multifocal intraocular lens in the ophthalmic specialty.
The approval statement describes the indicated use as primary implantation for visual correction of aphakia in adult patients with and without presbyopia after cataractous lens removal by phacoemulsification, for patients who desire near, intermediate, and distance vision with increased spectacle independence. The statement reports an intended purpose; it does not itself provide independent evidence of safety or clinical effectiveness.
FDA approval order statement
APPROVAL FOR THE TECNIS MULTIFOCAL FOLDABLE POSTERIOR CHAMBER INTRAOCULAR LENSES (IOLS), MODELS ZM900 AND ZMA00.THE DEVICES ARE INDICATED FOR PRIMARY IMPLANTATION FOR THE VISUAL CORRECTION OF APHAKIA ADULT PATIENTS WITH AND WITHOUT PRESBYOPIA IN WHOM A CATARACTOUS LENS HAS BEEN REMOVED BY PHACOEMULSIFICATION AND WHO DESIRE NEAR, INTERMEDIATE, AND DISTANCE VISION WITH INCREASED SPECTACLE INDEPENDENCE.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Jan 16, 2009
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P080010
- Regulatory pathway
- Premarket approval application
- Product code
- MFK
- Decision code
- APPR
- Decision date
- Jan 16, 2009
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lens, multifocal intraocular.
- Product code
- MFK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P080010 received
Application receipt date recorded by FDA.
P080010 · FDA decision
APPR
P080010/S032 · Related supplement
TECNIS Multi-focal 3-pc, Model ZMA00
Timeline entries are records held by MedtechLedger for P080010. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P080010
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TECNIS Multi-focal 3-pc, Model ZMA00P080010/S032 | Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
Explore the linked device profile
Other records with product code MFK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ClearView HD intraocular lens (IOL)P200020/S013 | Lenstec, Inc. | PMA supplement | Oct 23, 2026 | FDA |
| Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Sep 30, 2026 | FDA | |
| Rayner Intraocular Lenses , Ltd. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Johnson & Johnson Surgical Vision, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P080010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



